Mogrify has appointed Dr Jonathan Appleby as Chief Scientific Officer
Mogrify has announced the appointment of Dr Jonathan Appleby as Chief Scientific Officer.
With decades of industry experience in translating both conventional and advanced therapeutic medicines, Jonathan will lead advancement of the Company’s therapeutic programmes in areas including otology, ophthalmology and diabetes toward and into clinical development.
Jonathan is an accomplished medicines developer, having operated in all phases of therapeutic development from discovery to commercial launch.
He joins Mogrify from the Cell and Gene Therapy Catapult, where he was Executive Director and Chief Scientific Officer and led the R&D group focused on ATMP manufacturing processes and analytical development for five years.
Prior to this, Jon was CSO for Cell and Gene Therapy in GSK’s Rare Diseases Unit, where he led the team that developed Strimvelis, the first autologous paediatric CD34+ stem cell gene therapy to be approved for commercial use.
Jonathan previously held the position of Director and Portfolio Manager at the GSK Centre of Excellence for External Drug Development, where he discovered, in-licensed, and developed new technologies and assets across a broad range of therapeutic areas.
Jon enthused: “Mogrify’s proprietary platform for identifying and optimising transcription factor combinations capable of directly reprogramming cell function in vivo has the potential to address many diseases.”